These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26496700)

  • 21. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.
    Tremblay AM; Missiaglia E; Galli GG; Hettmer S; Urcia R; Carrara M; Judson RN; Thway K; Nadal G; Selfe JL; Murray G; Calogero RA; De Bari C; Zammit PS; Delorenzi M; Wagers AJ; Shipley J; Wackerhage H; Camargo FD
    Cancer Cell; 2014 Aug; 26(2):273-87. PubMed ID: 25087979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
    Yeung CL; Ngo VN; Grohar PJ; Arnaldez FI; Asante A; Wan X; Khan J; Hewitt SM; Khanna C; Staudt LM; Helman LJ
    Oncogene; 2013 Nov; 32(47):5429-38. PubMed ID: 23318429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
    Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
    J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostaglandin E
    Kim HB; Kim M; Park YS; Park I; Kim T; Yang SY; Cho CJ; Hwang D; Jung JH; Markowitz SD; Hwang SW; Yang SK; Lim DS; Myung SJ
    Gastroenterology; 2017 Feb; 152(3):616-630. PubMed ID: 27864128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-signal requirement for growth-promoting function of Yap in hepatocytes.
    Su T; Bondar T; Zhou X; Zhang C; He H; Medzhitov R
    Elife; 2015 Feb; 4():. PubMed ID: 25667983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NUAK2 is a critical YAP target in liver cancer.
    Yuan WC; Pepe-Mooney B; Galli GG; Dill MT; Huang HT; Hao M; Wang Y; Liang H; Calogero RA; Camargo FD
    Nat Commun; 2018 Nov; 9(1):4834. PubMed ID: 30446657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma.
    Diao Y; Guo X; Jiang L; Wang G; Zhang C; Wan J; Jin Y; Wu Z
    J Biol Chem; 2014 Jan; 289(1):529-39. PubMed ID: 24247238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
    Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
    Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKɛ-mediated phosphorylation.
    Wang S; Xie F; Chu F; Zhang Z; Yang B; Dai T; Gao L; Wang L; Ling L; Jia J; van Dam H; Jin J; Zhang L; Zhou F
    Nat Immunol; 2017 Jul; 18(7):733-743. PubMed ID: 28481329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Actin polymerization-enhancing drugs promote ovarian follicle growth mediated by the Hippo signaling effector YAP.
    Cheng Y; Feng Y; Jansson L; Sato Y; Deguchi M; Kawamura K; Hsueh AJ
    FASEB J; 2015 Jun; 29(6):2423-30. PubMed ID: 25690654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
    Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
    Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
    Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
    Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
    Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
    Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
    Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
    Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
    Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
    Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
    Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
    Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
    Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
    Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target.
    Shields CE; Potlapalli S; Cuya-Smith SM; Chappell SK; Chen D; Martinez D; Pogoriler J; Rathi KS; Patel SA; Oristian KM; Linardic CM; Maris JM; Haynes KA; Schnepp RW
    Mol Oncol; 2021 Aug; 15(8):2156-2171. PubMed ID: 33523558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
    Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
    Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.
    Makawita S; Ho M; Durbin AD; Thorner PS; Malkin D; Somers GR
    Pediatr Dev Pathol; 2009; 12(2):127-35. PubMed ID: 18788888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.